A team of OHSU researchers led by Jared Fischer, Ph.D., and Jose Montoya Mira, Ph.D., have developed a new blood test that identifies hard-to-detect pancreatic cancer with 85% accuracy. Fischer says, “The problem with pancreatic cancer is that we often catch it too late. Our goal with PAC-MANN is to give clinicians a tool that can detect the disease much earlier, when more treatment options are available and there is a better chance of survival.”

As the top recipient of research funding from NIH in the state, OHSU and its research is included in coverage of Oregon Attorney General Dan Rayfield’s lawsuit, along with 21 other states, to stop the NIH’s new policy on reduced indirect costs. Interim president Steve Stadum, J.D., says, “The research conducted at OHSU leads to life-saving therapies and technologies and contributes to the global effort that seeks to improve human health and well-being. Research is a foundational pillar of what makes us an academic health center, and we must do all we can to protect it.”

Media cover potential impacts to OHSU, Oregon and scientific research in the U.S. if the NIH reduction of indirect costs holds. “There’s 1,900 research workers at OHSU and I don’t think any of them feel safe. I know I don’t feel safe,” says Lynne Swarbrick, B.S.

OHSU hosts Sen. Ron Wyden, Sen. Jeff Merkley and Rep. Suzanne Bonamici in a press conference calling attention to the devastating impacts of reducing NIH indirect cost funding for OHSU and science in general. Peter Barr-Gillespie, Ph.D., says, ““If it goes through, it will cripple our ability to do biomedical research at OHSU.” Marc Freeman, Ph.D., says, “Everything we do depends on this robust NIH support. It’s as if you took your car to mechanic, and then someone said you can’t use 40% of your tools. It’s not a recipe for success.”

OHSU hosts Sen. Ron Wyden, Sen. Jeff Merkley and Rep. Suzanne Bonamici in a press conference calling attention to the devastating impacts of reducing NIH indirect cost funding for OHSU and science in general. Peter Barr-Gillespie, Ph.D., says, ““If it goes through, it will cripple our ability to do biomedical research at OHSU.” Marc Freeman, Ph.D., says, “Everything we do depends on this robust NIH support. It’s as if you took your car to mechanic, and then someone said you can’t use 40% of your tools. It’s not a recipe for success.”

OHSU hosts Sen. Ron Wyden, Sen. Jeff Merkley and Rep. Suzanne Bonamici in a press conference calling attention to the devastating impacts of reducing NIH indirect cost funding for OHSU and science in general. Peter Barr-Gillespie, Ph.D., says, ““If it goes through, it will cripple our ability to do biomedical research at OHSU.” Marc Freeman, Ph.D., says, “Everything we do depends on this robust NIH support. It’s as if you took your car to mechanic, and then someone said you can’t use 40% of your tools. It’s not a recipe for success.”

Interim President Steve Stadum, J.D., discusses challenges—including federal actions on research funding and patient care—and opportunities—including the proposed integration with Legacy—on the TV station’s long-form interview show, KGW Straight Talk. “OHSU has the resources, the capital to invest in Legacy's facilities, which is one of the commitments we've made, because Legacy's facilities are under-utilized. One of the goals of this merger, or acquisition, if you will, is to improve access. That means to reduce wait times. Wait times in the Portland area are unacceptably high. The status quo is definitely not working.”

OHSU — Oregon's largest research institution and the state's largest recipient of NIH grant money — would be hit the hardest.

Oregon’s U.S. Senators Jeff Merkley and Ron Wyden join an effort led by Washington State’s U.S. Senator Patty Murray in expressing serious alarm over the Trump Administration’s threats to cut the National Institutes of Health’s federal funding to research universities and institutions across American and in Oregon, including OHSU; the senators joined the entire Senate democratic caucus in signing a letter to Robert F. Kennedy, Jr., Secretary, U.S. Department of Health & Human Services.

Medscape reports on findings presented by Ava Mandelbaum, B.A., at the Society for Maternal-Fetal Medicine 2025 Annual Pregnancy Meeting, that conclude an interval of less than 1 year or at least 5 years between pregnancies was linked to an increased risk for adverse pregnancy outcomes in patients who had a history of preeclampsia.